RecruitingNot ApplicableNCT05502523

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

The Impact of Surgical Technique on Circulating Tumor DNA in Early-Stage Non-Small Cell Lung Cancer

Sponsor

Thomas Jefferson University

Enrollment

100 participants

Start Date

Aug 31, 2022

Study Type

INTERVENTIONAL

Conditions

Stage III Lung Cancer AJCC v8 Lung Non-Small Cell Carcinoma Stage II Lung Cancer AJCC v8 Stage I Lung Cancer AJCC v8

Summary

This clinical trial compares the effect of pulmonary vein-first surgical technique to pulmonary artery-first surgical technique in decreasing circulating tumor cell deoxyribonucleic acid (ctDNA) in patients with stage I-III non-small cell lung cancer. Pulmonary vein first and pulmonary artery first surgical techniques are standard surgical techniques for the division of the blood vessels during lung resection surgery. Pulmonary vein-first surgical technique may reduce the risk of shedding tumor cells during surgery and influence long term overall survival.

Eligibility

Min Age: 18 Years

Inclusion Criteria2

Any patients 18 years of age or older with confirmed or suspected early-stage (stage I-III) NSCLC
Eligible and scheduled for surgical anatomic lung resection (e.g. lobectomy or segmentectomy) as routine clinical care for their disease

Exclusion Criteria3

Previous cancer diagnosis within 5 years (except ductal carcinoma in situ \[DCIS\] of the breast, superficial bladder cancer, non-melanoma skin primary, other malignancy that does not require treatment).
Preoperative chemotherapy, immunotherapy, or radiation therapy
Receipt of perioperative blood transfusion